Floatz logo

T-Cell Receptor-Engineered T-Cells

Prostate Carcinoma

Fred Hutchinson Cancer CenterCell therapyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
81/ 100

Competitive context

114 Active assets in the Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Enzalutamide
Pfizer
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

T-Cell Receptor-Engineered T-Cells is also rated in:

prostate small cell carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
40 / 100
View asset →
metastatic malignant neoplasmDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →